S. Korea Doubles Number Of Asbestos-Tainted Drugs Allowed On Sale
This article was originally published in PharmAsia News
Executive Summary
South Korea's FDA has decided to add 11 more drugs believed tainted with asbestos to remain for sale through May 8. The decision increases the number of asbestos-tainted medicines allowed to remain on the market to 22 out of the 1,122 identified by the agency as possibly contaminated with the carcinogen (PharmAsia News, April 10, 2009). The agency eased the restrictions for the 22 on grounds there were no suitable replacements for them. The other 1,100 drugs have been banned and removed from store shelves if they were made before April 3, when the agency issued a ban on the use of talc to remove asbestos. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.